A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and
tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two
groups of subjects with metastatic castration-resistant prostate cancer (mCRPC). One group
comprises subjects who must have received at least one taxane-containing chemotherapy regimen
(e.g. docetaxel, cabazitaxel). The second group comprises subjects who are cytotoxic
chemotherapy-naïve. Subjects who are cytotoxic chemotherapy-naïve must have received and
progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to
Radium-223. Both groups of subjects must also have received and progressed on abiraterone
acetate and/or enzalutamide. If a subject is unable to receive abiraterone acetate and/or
enzalutamide, Sponsor approval is required for participation in the study. Subjects will
receive up to eight doses of PSMA ADC approximately once every three weeks.